DALLAS--(BUSINESS WIRE)--Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today ...

Scientists have long known that the Alzheimer’s brain often features abnormal plaques and tangles, and recent studies have highlighted the role that the brain’s vascular system plays in disease ...

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (CERS) announced today that it will host an industry workshop on the benefits of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly ...

Additional Funding to Support Randomized Study Evaluating Earlier Access to INTERCEPT Fibrinogen Complex in Trauma Associated Hemorrhagic Shock Patients Cerus Corporation (Nasdaq: CERS) announced ...

The top panel, designed with BioRender.com, illustrates the process of clot formation and lysis, beginning with platelet aggregation and activation of the coagulation cascade, followed by the ...

IFC is a pathogen reduced blood component for fibrinogen supplementation with a 5-day post-thaw shelf life. IFC contains fibrinogen, factor XIII, von Willebrand factor and other key clotting factors ...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from ...

Additional Funding to Support Randomized Study Evaluating Earlier Access to INTERCEPT Fibrinogen Complex in Trauma Associated Hemorrhagic Shock Patients The additional funding will support CRYO-FIRST, ...

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that it has been awarded an additional $7.2 million contract amendment by the U.S. Department of Defense (DoD) ...